Evidence map›Paper›PMID 17708420›Full record

ArticleGene expression2007

Gene expression analysis in myotonic dystrophy: indications for a common molecular pathogenic pathway in DM1 and DM2.

Annalisa Botta, Laura Vallo, Fabrizio Rinaldi, Emanuela Bonifazi, Francesca Amati, Michela Biancolella, Stefano Gambardella, Enzo Mancinelli, Corrado Angelini, Giovanni Meola and 1 more

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Gene expression, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
0.5field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. The polyG diseases: a new disease entity.Acta neuropathologica communications · 2022
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. (CCUG)Disease models & mechanisms · 2017
    Article
  13. Review
  14. Article
  15. Article
  16. ClC1 chloride channel in myotonic dystrophy type 2 and ClC1 splicing in vitro.Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology · 2012
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Annalisa BottaDepartment of Biopathology, Tor Vergata University of Rome, Rome, Italy. abottait@yahoo.it
Laura Vallo
Fabrizio Rinaldi
Emanuela Bonifazi
Francesca Amati
Michela Biancolella
Stefano Gambardella
Enzo Mancinelli
Corrado Angelini
Giovanni Meola
Giuseppe Novelli
University of Rome Tor Vergata · ITIstituto Neurologico Mediterraneo · ITIRCCS Policlinico San Donato · ITIRCCS San Camillo Hospital · ITPoliclinico Tor Vergata · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An RNA gain-of-function of expanded transcripts is the most accredited molecular mechanism for myotonic dystrophy type 1 (DM1) and 2 (DM2). To disclose molecular parallels and divergences in pathogenesis of both disorders, we compared the expression profile of muscle biopsies from DM1 and DM2 patients to controls. DM muscle tissues showed a reduction in the major skeletal muscle chloride channel (CLCN1) and transcription factor Sp1 transcript levels and an abnormal processing of the CLCN1 and insulin receptor (IR) pre-mRNAs. No essential differences were observed in the muscle blind-like gene (MBNL1) and CUG binding protein 1 (CUGBP1) transcript levels as well as in the splicing pattern of the myotubularin-related 1 (MTMR1) gene. Macroarray analysis of 96 neuroscience-related genes revealed a considerable similar expression profile between the DM samples, reflective of a common muscle pathology origin. Using a twofold threshold, we found six misregulated genes important in calcium and potassium metabolism and in mitochondrial functions. Our results indicate that the DM1 and DM2 overlapping clinical phenotypes may derive from a common trans acting mechanism that traps and influences shared genes and proteins. An RNA gain-of-function of expanded transcripts is the most accredited molecular mechanism for myotonic dystrophy type 1 (DM1) and 2 (DM2). To disclose molecular parallels and divergences in pathogenesis of both disorders, we compared the expression profile of muscle biopsies from DM1 and DM2 patients to controls. DM muscle tissues showed a reduction in the major skeletal muscle chloride channel (CLCN1) and transcription factor Sp1 transcript levels and an abnormal processing of the CLCN1 and insulin receptor (IR) pre-mRNAs. No essential differences were observed in the muscle blind-like gene (MBNL1) and CUG binding protein 1 (CUGBP1) transcript levels as well as in the splicing pattern of the myotubularin-related 1 (MTMR1) gene. Macroarray analysis of 96 neuroscience-related genes revealed a considerable similar expression profile between the DM samples, reflective of a common muscle pathology origin. Using a twofold threshold, we found six misregulated genes important in calcium and potassium metabolism and in mitochondrial functions. Our results indicate that the DM1 and DM2 overlapping clinical phenotypes may derive from a common trans acting mechanism that traps and influences shared genes and proteins.

Indexed as

Gene Expression RegulationAdultAlternative SplicingBiopsyChloride ChannelsFemaleGene Expression ProfilingGenes, MHC Class IIHumansIon ChannelsMaleMusclesMyotonic DystrophyOligonucleotide Array Sequence AnalysisProtein Tyrosine Phosphatase, Non-Receptor Type 1Protein Tyrosine PhosphatasesChloride ChannelsCLC-1 channelIon ChannelsMTMR1 protein, humanProtein Tyrosine Phosphatase, Non-Receptor Type 1Protein Tyrosine PhosphatasesProtein Tyrosine Phosphatases, Non-Receptor

Identifiers

PMID17708420
PMCPMC6032453
OpenAlexW2026906833

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.